Supplementary Figure 1. Death-censored graft and patient survival of the entire cohort according to induction therapy. (A) Death-censored graft survival in the entire cohort (p = 0.46). (B) Patient survival in the entire cohort (basiliximab, 93.0%; ATG, 94.4%; p = 0.68). ATG, antithymocyte globulin.